Although POLE mutation status has been incorporated into clinical studies for ICI,27,28 and inhibition of ATM and ATR was shown to influence immunotherapy response in model systems,4 how DNA polymerase and damage sensor deficiencies affect the tumor immune microenvironment and sensitivity to ICI therapy is unclear. This evidence concerns the gene ATM and neoplasm.